FDA's delay in publishing conflict-of-interest final reg draws inquiry from Rep. Barton.
This article was originally published in The Tan Sheet
Executive Summary
FDA CONFLICT OF INTEREST POLICY DELAY QUESTIONED BY REP. BARTON in a Jan. 4 letter to FDA Commissioner David Kessler. House Com-merce/Oversight Chairman Joe Barton (R-Tex.) wrote that "although the comment period for" FDA's proposed rule on clinical investigator conflict of interest "ended over one year ago, to date, and you as a commissioner have personally placed importance on dealing with conflict of interest issues, your agency has failed to take final action on this rulemaking, already missing the initial publication date of October 1995."
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning